FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $38.6M.
Where they traded
Last open-market purchase: July 17, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Buy | 50,945 | $3.52 | $179.3K | 7,080,945 | |||
| Buy | 116,671 | $3.56 | $415.3K | 7,030,000 | |||
| Buy | 107,377 | $3.56 | $382.3K | 6,913,329 | |||
| 2 fills | Buy | 129,603 | $3.57 | $462.9K | 6,805,952 | ||
| Buy | 12,966 | $3.54 | $45.9K | 6,676,349 | |||
| Ezekowitz Alan | Director | Sell | 18,000 | $3.65 | $65.6K | 10,927 −62.2% of holding | |
| Gould Robert J | Director | Sell | 15,000 | $10.72 | $160.9K | 454,864 −3.2% of holding | |
| Gould Robert J 2 fills | Director | Sell | 30,000 | $11.37 | $341.2K | 469,864 −6% of holding | |
| Oltmans Curtis Gale | Chief Legal Officer | Sell | 3,452 | $12.92 | $44.6K | 10,252 −25.2% of holding | |
| 3 fills | Sell | 4,175,139 | $13.98 | $58.4M | 8,852,079 −32% of holding | ||
| Gould Robert J | Director | Sell | 15,000 | $11.03 | $165.5K | 484,864 −3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.